Natixis
AVXL icon

Natixis’s Anavex Life Sciences AVXL Stock Holding History

Natixis’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$932 Buy
+360
New +$1.06K ﹤0.01% 1118
2023
Q3 		– Sell
-8,000
Closed -$65K – 983
2023
Q2 		$65K Buy
+8,000
New +$68.6K ﹤0.01% 824

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Summit Financial
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Natixis's AVXL Position: Q2 2026 in Review

Natixis opened a new position in Anavex Life Sciences (AVXL) in Q2 2026: 360 shares worth $932. The stake represents ﹤0.01% of the portfolio and ranks #1118 among its holdings. This is a return to the name: Natixis previously reported a position in AVXL as recently as Q2 2023.

Natixis first reported a position in AVXL in Q2 2023 and has held it in 2 quarters since. The position peaked at $65K in Q2 2023. 180 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Natixis held 360 shares of Anavex Life Sciences worth $932 as of Q2 2026.
  • Anavex Life Sciences was a new Natixis position in Q2 2026.
  • Anavex Life Sciences made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #1118 holding.
  • Natixis first reported a position in Anavex Life Sciences in Q2 2023 and has held it in 2 quarters since.
  • Natixis's Anavex Life Sciences position peaked at $65K in Q2 2023.
  • 180 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.